NCPA April 13, 2021
SPRINGFIELD, Ill. (April 13, 2021) The Illinois Pharmacists Association supports a bipartisan bill introduced in the Illinois Legislature by Senate Assistant Majority Leader David Koehler (D-Peoria). Senate Bill 2008 (SB2008) is designed to help correct the imbalance of pharmacy benefit manager power and incorporates patient access and reimbursement regulations. This bill not only has the full support of the IPhA and the National Community Pharmacists Association, but also several other health care advocacy groups, including the Illinois Council of Health-System Pharmacists and Illinois Association of Long-Term Care Pharmacy Providers.
IPhA Executive Director Garth Reynolds will be testifying in support of SB2008 at a hearing on Wednesday, April 14. NCPA Director of State Government Affairs Matt Magner will also testify at the hearing in support of the legislation. Also speaking are Ben Calcaterra, co-owner of Calcate
Duphat 2021 to attract over 20,000 visitors
Dubai, UAE, 10 days ago The 26th edition of Dubai International Pharmaceuticals & Technologies Conference & Exhibition- Duphat, will kick off tomorrow - April 5, at the Dubai World Trade Centre in Dubai, UAE. The highly anticipated Duphat 2021 is expected to attract over 20,000 visitors and participants from 75 countries over the course of three-days, according to a
Wam report. Organised annually by Index Conferences and Exhibitions – a member of Index Holding, the conference is set to witness the participation of 40 speakers who will offer their deep insights during 40 scientific sessions related to the top trending topics in the pharmaceutical industry. The pharma event will include 300 poster presentations and various workshops to discuss the latest scientific research in pharmacy and also improve the awareness and understanding of the latest trends in the pharma industry.
7 Min Read
Social media users have been sharing posts which claim that “hydroxychloroquine is now ok” yet the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the American Medical Association (AMA) told Reuters that their guidance advising against treating COVID-19 with hydroxychloroquine or urging caution reflects their current positions, as of this article’s publication.
Examples of the posts can be seen here , here and here .
Hydroxychloroquine is a medicine that is FDA-approved to treat arthritis and to treat or prevent malaria (here). Former U.S. President Trump said last March that hydroxychloroquine could be a game-changer in the coronavirus pandemic. He also said he was taking it himself, even after the FDA advised that its efficacy and safety were unproven (here).
To embed, copy and paste the code into your website or blog:
On March 29, 2021, Judge Margaret B. Seymour, in the United States District Court for the District of South Carolina, set aside a decision from CMS’s Provider Reimbursement Review Board (Board) denying reimbursement relating to a hospital’s pharmacy residency program. The issue before the court was whether the Medical University Hospital Authority (MUHA) “operated” its pharmacy residency program under the requirements of 42 C.F.R. § 413.85(f)(1) such that MUHA was entitled to reimbursement for the pass-through costs of that program. The court determined that the Board construed section 413.85(f)(1) “too narrowly” and that MUHA was entitled to Medicare reimbursement because it was the operator of the program. The hospital was represented by Dan Hettich of King & Spalding in conjunction with local counsel.
(Photo by Kathrin Ziegler/Getty Images)
The practice known as white bagging is exacerbating supply chain security challenges and jeopardizing patient safety, the American Society of Health-System Pharmacists and the American Hospital Association told acting Food and Drug commissioner Dr. Janet Woodcock in a March 31 letter.
ASHP and AHA strongly encouraged the FDA to consider the patient safety and supply chain security risks of white bagging, and take appropriate enforcement action, according to the March 31 letter sent by AHA Executive Vice President Thomas P. Nickels and Tom Kraus, vice president of Government Relations for the American Society of Health-System Pharmacists.